Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (48)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rubio, G.
Right arrow Articles by Palomo, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rubio, G.
Right arrow Articles by Palomo, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Alcohol and Alcoholism Vol. 36, No. 5, pp. 419-425, 2001
© 2001 Medical Council on Alcohol

NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT

G. Rubio,*, M. A. Jiménez-Arriero, G. Ponce and T. Palomo

Psychiatric Service, ‘12 de Octubre’ University Hospital, Madrid, Spain

Received 29 December 2000; first review notified 16 March 2001; accepted 2 April 2001

— Naltrexone and acamprosate reduce relapse in alcohol dependence. They have not yet been compared in a published trial. The aim of this study was to compare the efficacy of these compounds in conditions similar to those in routine clinical practice. Random allocation to a year of treatment with naltrexone (50 mg/day) or acamprosate (1665–1998 mg/day) was made in 157 recently detoxified alcohol-dependent men with moderate dependence (evaluated using the Addictions Severity Index and Severity of Alcohol Dependence Scale). All were patients whom a member of the family would accompany regularly to appointments. Alcohol consumption, craving and adverse events were recorded weekly for the first 3 months, and then bi-weekly, by the treating psychiatrist who was not blinded. At 3-monthly intervals, investigators who were blinded to the treatment documented patients' alcohol consumption based on patients' accounts, information given by the psychiatrists when necessary, and reports from patients' families. Serum gamma-glutamyltransferase (GGT) was also measured. Efforts were made to sustain the blindness of the investigators. The same investigator did not assess the same patient twice. The integrity of the blindness was not checked. There was no difference between treatments in mean time to first drink (naltrexone 44 days, acamprosate 39 days) but the time to first relapse (five or more drinks in a day) was 63 days (naltrexone) versus 42 days (acamprosate) (P = 0.02). At the end of 1 year, 41% receiving naltrexone and 17% receiving acamprosate had not relapsed (P = 0.0009). The cumulative number of days of abstinence was significantly greater, and the number of drinks consumed at one time and severity of craving were significantly less, in the naltrexone group compared to the acamprosate group, as was the percentage of heavy drinking days (P = 0.038). More patients in the acamprosate than the naltrexone group were commenced on disulfiram during the study. Naltrexone patients attended significantly more group therapy sessions, though this could not explain their better outcome. There were non-significant trends for the naltrexone group to comply better with medication, to stay in the study longer, and to show greater improvement over baseline in serum GGT.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Alcohol AlcoholHome page
G. RUBIO, G. PONCE, R. RODRIGUEZ-JIMENEZ, M. A. JIMENEZ-ARRIERO, J. HOENICKA, and T. PALOMO
CLINICAL PREDICTORS OF RESPONSE TO NALTREXONE IN ALCOHOLIC PATIENTS: WHO BENEFITS MOST FROM TREATMENT WITH NALTREXONE?
Alcohol Alcohol., May 1, 2005; 40(3): 227 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
A. DE SOUSA and A. DE SOUSA
A ONE-YEAR PRAGMATIC TRIAL OF NALTREXONE VS DISULFIRAM IN THE TREATMENT OF ALCOHOL DEPENDENCE
Alcohol Alcohol., November 1, 2004; 39(6): 528 - 531.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. R. Lingford-Hughes, S. Welch, and D. J. Nutt
Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology
J Psychopharmacol, September 1, 2004; 18(3): 293 - 335.
[PDF]

Home page
 The Annals of PharmacotherapyHome page
G. P Overman, C. J Teter, and S. K Guthrie
Acamprosate for the Adjunctive Treatment of Alcohol Dependence
Ann. Pharmacother., July 1, 2003; 37(7): 1090 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
F. Kiefer, H. Jahn, T. Tarnaske, H. Helwig, P. Briken, R. Holzbach, P. Kampf, R. Stracke, M. Baehr, D. Naber, et al.
Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study
Arch Gen Psychiatry, January 1, 2003; 60(1): 92 - 99.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. Rubio, G. Ponce, J. Manzanares, J. D. Sinclair, H. Alho, M. Shinderman, J. H. Krystal, J. A. Cramer, and R. Rosenheck
Naltrexone for Alcohol Dependence
N. Engl. J. Med., April 25, 2002; 346(17): 1329 - 1331.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.